Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Director Richard K. Prins sold 16,598 shares of the firm’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $19.90, for a total value of $330,300.20. Following the sale, the director now directly owns 45,442 shares of the company’s stock, valued at approximately $904,295.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Amphastar Pharmaceuticals stock opened at $19.01 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.79 and a debt-to-equity ratio of 0.12. Amphastar Pharmaceuticals Inc has a 52 week low of $13.15 and a 52 week high of $20.45. The company has a market capitalization of $881.13, a price-to-earnings ratio of 50.03, a PEG ratio of 1.35 and a beta of 1.42.

How to Become a New Pot Stock Millionaire

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Monday, March 12th. The company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The firm had revenue of $60.40 million during the quarter, compared to analysts’ expectations of $60.62 million. During the same quarter last year, the firm posted $0.01 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. research analysts predict that Amphastar Pharmaceuticals Inc will post 0.63 EPS for the current year.

A number of institutional investors have recently made changes to their positions in AMPH. Parametric Portfolio Associates LLC grew its stake in Amphastar Pharmaceuticals by 72.0% in the second quarter. Parametric Portfolio Associates LLC now owns 45,615 shares of the company’s stock valued at $815,000 after acquiring an additional 19,091 shares during the period. The Manufacturers Life Insurance Company grew its stake in Amphastar Pharmaceuticals by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after acquiring an additional 312 shares during the period. Prudential Financial Inc. grew its stake in Amphastar Pharmaceuticals by 8.3% in the third quarter. Prudential Financial Inc. now owns 63,580 shares of the company’s stock valued at $1,136,000 after acquiring an additional 4,850 shares during the period. BNP Paribas Arbitrage SA grew its stake in Amphastar Pharmaceuticals by 70.2% in the third quarter. BNP Paribas Arbitrage SA now owns 17,946 shares of the company’s stock valued at $321,000 after acquiring an additional 7,401 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its stake in Amphastar Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,390 shares of the company’s stock valued at $239,000 after acquiring an additional 4,960 shares during the period. 44.46% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts recently commented on AMPH shares. Zacks Investment Research cut Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. BidaskClub cut Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th. Piper Jaffray reaffirmed a “buy” rating and set a $26.00 target price on shares of Amphastar Pharmaceuticals in a research note on Tuesday, January 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 target price (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $21.33.

ILLEGAL ACTIVITY NOTICE: “Richard K. Prins Sells 16,598 Shares of Amphastar Pharmaceuticals Inc (AMPH) Stock” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/09/amphastar-pharmaceuticals-inc-amph-director-richard-k-prins-sells-16598-shares-of-stock.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply